HRP960196A2 - NOVEL USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) - Google Patents
NOVEL USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) Download PDFInfo
- Publication number
- HRP960196A2 HRP960196A2 HR19515275.1A HRP960196A HRP960196A2 HR P960196 A2 HRP960196 A2 HR P960196A2 HR P960196 A HRP960196 A HR P960196A HR P960196 A2 HRP960196 A2 HR P960196A2
- Authority
- HR
- Croatia
- Prior art keywords
- same
- adenosyl
- methionine
- ischemia
- day
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010073681 Epidural haemorrhage Diseases 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- FUDAIDRKVVTJFF-UHFFFAOYSA-N butane-1,1-disulfonic acid Chemical compound CCCC(S(O)(=O)=O)S(O)(=O)=O FUDAIDRKVVTJFF-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19515275A DE19515275A1 (de) | 1995-04-26 | 1995-04-26 | Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP960196A2 true HRP960196A2 (en) | 1998-02-28 |
Family
ID=7760373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR19515275.1A HRP960196A2 (en) | 1995-04-26 | 1996-04-24 | NOVEL USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0822820A1 (fr) |
| JP (1) | JPH11504023A (fr) |
| KR (1) | KR19990008061A (fr) |
| CN (1) | CN1182367A (fr) |
| AR (1) | AR001687A1 (fr) |
| AU (1) | AU5646396A (fr) |
| CA (1) | CA2216854A1 (fr) |
| CZ (1) | CZ330597A3 (fr) |
| DE (1) | DE19515275A1 (fr) |
| HR (1) | HRP960196A2 (fr) |
| IL (1) | IL117844A0 (fr) |
| MX (1) | MX9707735A (fr) |
| NO (1) | NO974941D0 (fr) |
| WO (1) | WO1996033727A1 (fr) |
| ZA (1) | ZA963296B (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE37913B1 (en) * | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
| JPS59139319A (ja) * | 1983-01-31 | 1984-08-10 | Fuji Kagaku Kogyo Kk | 脳障害による身体機能障害治療剤 |
| JPH02290896A (ja) * | 1989-04-28 | 1990-11-30 | Fuji Kagaku Kogyo Kk | 新規なｓ―アデノシルメチオニン誘導体 |
| DE4425280C2 (de) * | 1994-07-16 | 1997-05-07 | Knoll Ag | Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden |
-
1995
- 1995-04-26 DE DE19515275A patent/DE19515275A1/de not_active Withdrawn
-
1996
- 1996-04-08 IL IL11784496A patent/IL117844A0/xx unknown
- 1996-04-13 MX MX9707735A patent/MX9707735A/es unknown
- 1996-04-13 EP EP96913500A patent/EP0822820A1/fr not_active Withdrawn
- 1996-04-13 CZ CZ973305A patent/CZ330597A3/cs unknown
- 1996-04-13 CA CA002216854A patent/CA2216854A1/fr not_active Abandoned
- 1996-04-13 AU AU56463/96A patent/AU5646396A/en not_active Abandoned
- 1996-04-13 JP JP8532131A patent/JPH11504023A/ja active Pending
- 1996-04-13 WO PCT/EP1996/001570 patent/WO1996033727A1/fr not_active Application Discontinuation
- 1996-04-13 CN CN96193498A patent/CN1182367A/zh active Pending
- 1996-04-13 KR KR1019970707585A patent/KR19990008061A/ko not_active Application Discontinuation
- 1996-04-23 AR AR33625596A patent/AR001687A1/es unknown
- 1996-04-24 HR HR19515275.1A patent/HRP960196A2/hr not_active Application Discontinuation
- 1996-04-25 ZA ZA9603296A patent/ZA963296B/xx unknown
-
1997
- 1997-10-24 NO NO974941A patent/NO974941D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO974941L (no) | 1997-10-24 |
| CZ330597A3 (cs) | 1998-02-18 |
| EP0822820A1 (fr) | 1998-02-11 |
| JPH11504023A (ja) | 1999-04-06 |
| AU5646396A (en) | 1996-11-18 |
| KR19990008061A (ko) | 1999-01-25 |
| MX9707735A (es) | 1997-12-31 |
| NO974941D0 (no) | 1997-10-24 |
| CN1182367A (zh) | 1998-05-20 |
| IL117844A0 (en) | 1996-08-04 |
| AR001687A1 (es) | 1997-11-26 |
| DE19515275A1 (de) | 1996-10-31 |
| ZA963296B (en) | 1997-10-27 |
| CA2216854A1 (fr) | 1996-10-13 |
| WO1996033727A1 (fr) | 1996-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagano et al. | Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis | |
| Cheung et al. | Neuroprotection in glaucoma: drug-based approaches | |
| Ho et al. | Tetramethylpyrazine for treatment of experimentally induced stroke in Mongolian gerbils. | |
| DE69522578T2 (de) | Glial neurotropher faktor als nervenschutzmittel | |
| CZ355897A3 (cs) | Způsob léčení mánie a bipolárních poruch | |
| Yao et al. | Failure of MK-801 to reduce infarct volume in thrombotic middle cerebral artery occlusion in rats. | |
| US6268396B1 (en) | Use of valproic acid analog for the treatment and prevention of migraine and affective illness | |
| Lipartiti et al. | Monosialoganglioside GM1 reduces NMDA neurotoxicity in neonatal rat brain | |
| US6090775A (en) | Treatment of neurological conditions by an interleukin-1 inhibiting compound | |
| EP0305181B1 (fr) | Ethyl-(+)-apovincaminat pour le traitement des symptômes cliniques de la démyélinisation d'origine autoimmune | |
| HRP960196A2 (en) | NOVEL USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) | |
| DE4425280C2 (de) | Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden | |
| RU2689384C1 (ru) | Применение холиновой соли янтарной кислоты в производстве средств лечения черепно-мозговой травмы | |
| GB2595077A (en) | Combination of gaboxadol and lithium for the treatment of psychiatric disorders | |
| Malhotra et al. | The effect of intra (cerebro) ventricular reserpine on the acetylcholine content of the heart, ileum and hypothalamus of the dog | |
| Scholtes et al. | Generalized convulsive status epilepticus: pathophysiology and treatment | |
| Nattero et al. | Reserpine for migraine prophylaxis | |
| DE69114261T2 (de) | Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit. | |
| Hamaguchi et al. | Does hypertonic saline have preventive effects against delayed neuronal death in gerbil hippocampus? | |
| Gelmers | A trial with nimodipine, a calcium entry blocker for the prevention and treatment of ischaemic brain damage | |
| KR20210127326A (ko) | 신경아교세포의 아밀로이드-베타 대식작용을 증가시키는 화합물을 유효성분으로 퇴행성 뇌질환 치료용 약학적 조성물 | |
| McEntee et al. | Pharmacological treatments of age-related cognitive loss | |
| WO2024184475A1 (fr) | Combinaison de metformine et de glibenclamide dans le traitement de la maladie de parkinson | |
| AIHARA et al. | Nitrendipine facilitates recovery of cerebral blood flow, EEG and metabolites following cerebral ischemia in anesthetized rabbits | |
| MXPA97000439A (en) | Use of (s) -adenosil-l-metionine (same) and its salesphisiologically compatible for treatment of reperfusion damage activated by focal tempo ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ODBC | Application rejected |